Plenary Session I: Lung Cancer Advances: Evolving Treatment Paradigms in Operable NSCLC| Presented at the 2025 International Thoracic Surgical Oncology Summit

This CME-accredited plenary session highlights the latest breakthroughs in the management of operable non-small cell lung cancer (NSCLC). Expert faculty explore advances in screening, targeted therapies, molecular residual disease assessment, and the integration of novel agents into multimodal treatment strategies. The session also features the distinguished G. Alexander Patterson Giant’s Lecture, addressing how science and policy intersect to expand access to life-saving lung cancer screening.

Featured Presentations:
• Introduction
• G. Alexander Patterson Giant’s Lecture: Lung Cancer Screening — Saving Lives with Science and Policy
• Access to Lung Cancer Screening Resources for Patients in High-Risk Areas
• Surgical Outcomes Following Neoadjuvant Osimertinib (OSI) ± Chemotherapy (CT) vs CT Alone in Patients with Resectable, Epidermal Growth Factor Receptor-Mutated (EGFRm) Stage II–IIIB NSCLC: NeoADAURA
• Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFR-Mutated NSCLC
• What is the Optimal Treatment Approach for Stage II–III Lung Adenocarcinoma with an EGFR/ALK Oncogenic Driver?
• mRNA Vaccines in NSCLC: From Proof of Concept to Clinical Trials
• Targeted Therapy for Uncommon Oncogenic Driver Alterations in Locoregionally Advanced NSCLC: The Nautica Update
• Discussion

Course summary
Available credit: 
  • 2.00 ABS Accredited CME

    Successful completion of this CME activity, [which includes participation in the evaluation component], enables the learner to earn credit toward the CME [and Self-Assessment] requirement(s) of the American Board of Surgery Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
  • 2.00 ABTS Accredited CME
    Successful completion of this CME activity, [which includes participation in the evaluation component], enables the learner to earn credit toward the CME [and Self-Assessment / Patient Safety / Performance in Practice requirements] of the American Board of Thoracic Surgery’s Maintenance of Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.
  • 2.00 AMA PRA Category 1 Credit(s)™
    The American Association for Thoracic Surgery designates this for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Participation
Course opens: 
11/05/2025
Course expires: 
09/25/2028
Cost:
$200.00

The planners and faculty for this activity did not have any relevant relationships with ACCME-defined ineligible companies to disclose unless listed PDF icon here. All relevant relationships were mitigated prior to the start of the activity according to The Standards for Integrity and Independence in Accredited Continuing Education.

 

 

Purpose (Desired Learning Outcome) 

 Following this session, leaners should be able to apply current guidelines and evidence-based strategies to increase access to and utilization of lung cancer screening as well as understand the principles and clinical applications of MRD analysis and targeted theater rin guiding treatment response and recurrence monitoring. 

ACCME Accreditation Statement

The American Association for Thoracic Surgery is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement 

The American Association for Thoracic Surgery designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

The 2025 AATS International Thoracic Surgical Oncology Summit received commercial support from:

  • Karl Storz

Available Credit

  • 2.00 ABS Accredited CME

    Successful completion of this CME activity, [which includes participation in the evaluation component], enables the learner to earn credit toward the CME [and Self-Assessment] requirement(s) of the American Board of Surgery Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
  • 2.00 ABTS Accredited CME
    Successful completion of this CME activity, [which includes participation in the evaluation component], enables the learner to earn credit toward the CME [and Self-Assessment / Patient Safety / Performance in Practice requirements] of the American Board of Thoracic Surgery’s Maintenance of Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.
  • 2.00 AMA PRA Category 1 Credit(s)™
    The American Association for Thoracic Surgery designates this for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Participation

Price

Cost:
$200.00
Please login or register to take this course.